DelveInsight’s, “Relapsing Remitting Multiple Sclerosis Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in the Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing Remitting Multiple Sclerosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Relapsing Remitting Multiple Sclerosis Pipeline Report

• DelveInsight’s Relapsing Remitting Multiple Sclerosis pipeline report depicts a robust space with 25+ active players working to develop 28+ pipeline therapies for Relapsing Remitting Multiple Sclerosis treatment.
• The leading companies working in the Relapsing Remitting Multiple Sclerosis Market include Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda, and others.
• Promising Relapsing Remitting Multiple Sclerosis Pipeline Therapies in the various stages of development include Ocrelizumab, Fingolimod, ALKS 8700, Dimethyl Fumarate, BG00002 (natalizumab), dirucotide, Rebif®, Copaxone®, and others.
• August 2023: Biogen announced a study of phase 4 clinical trials for peginterferon beta-1a. The primary objective of this study is to investigate whether Peg-IFN beta-1a improves the satisfaction of Relapsing-Remitting Multiple Sclerosis (RRMS) participants unsatisfied with injectable subcutaneous Interferons, as measured by the Abbreviated Treatment Satisfaction Questionnaire to Medication (TSQM-9), at 12 weeks.
• September 2023: Hoffmann-La Roche announced a study of phase 3 clinical trials for Ocrelizumab and Fingolimod. This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.

 

Request a sample and discover the recent advances in Relapsing Remitting Multiple Sclerosis Treatment Drugs @ Relapsing Remitting Multiple Sclerosis Pipeline Report

 

In the Relapsing Remitting Multiple Sclerosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Relapsing Remitting Multiple Sclerosis clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Relapsing Remitting multiple sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Relapsing Remitting Multiple Sclerosis Overview

The term multiple sclerosis refers to the distinctive areas of scar tissue (sclerosis – also called plaques or lesions) that result from the attack on myelin by the immune system. These plaques are visible using magnetic resonance imaging in the white and/or gray matter of people who have MS. Plaques can be as small as a pinhead or as large as a golf ball.

 

Find out more about Relapsing Remitting Multiple Sclerosis Therapeutics Assessment @ Relapsing Remitting Multiple Sclerosis Preclinical and Discovery Stage Products

 

Relapsing Remitting Multiple Sclerosis Emerging Drugs Profile

• IMU-838: Immunic AG
• Tolebrutinib: Sanofi
• Telitacicept: RemeGen
• ANK700: Anokion

 

Relapsing Remitting Multiple Sclerosis Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the Relapsing Remitting Multiple Sclerosis therapies. The Relapsing Remitting Multiple Sclerosis companies which have their Relapsing Remitting multiple sclerosis drug candidates in the most advanced stage, i.e. Phase III include, Immunic.

 

Learn more about the emerging Relapsing Remitting Multiple Sclerosis Pipeline Therapies @ Relapsing Remitting Multiple Sclerosis Clinical Trials Assessment

 

Scope of the Relapsing Remitting Multiple Sclerosis Pipeline Report

• Coverage- Global
• Relapsing Remitting Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Relapsing Remitting Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Relapsing Remitting Multiple Sclerosis Companies- Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda, and others.
• Relapsing Remitting Multiple Sclerosis Pipeline Therapies- Ocrelizumab, Fingolimod, ALKS 8700, Dimethyl Fumarate, BG00002 (natalizumab), dirucotide, Rebif®, Copaxone®, and others.

 

Dive deep into rich insights for new drugs for Relapsing Remitting Multiple Sclerosis treatment, Visit @ Relapsing Remitting Multiple Sclerosis Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Relapsing-Remitting Multiple Sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Relapsing-Remitting Multiple Sclerosis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. IMU-838: Immunic AG
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Telitacicept: RemeGen
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ANK700: Anokion
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Relapsing-Remitting Multiple Sclerosis Key Companies
21. Relapsing-Remitting Multiple Sclerosis Key Products
22. Relapsing-Remitting Multiple Sclerosis- Unmet Needs
23. Relapsing-Remitting Multiple Sclerosis- Market Drivers and Barriers
24. Relapsing-Remitting Multiple Sclerosis- Future Perspectives and Conclusion
25. Relapsing-Remitting Multiple Sclerosis Analyst Views
26. Relapsing-Remitting Multiple Sclerosis Key Companies
27. Appendix

 

For further information on the Relapsing Remitting Multiple Sclerosis pipeline therapeutics, reach out to Relapsing Remitting Multiple Sclerosis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking